TNYA: Tenaya Therapeutics Company Current Liabilities

TNYA (Tenaya Therapeutics) - company brandmark

The market price action of Tenaya Therapeutics (TNYA), which specializes in cardiology solutions, reflects the 0.00 metric. This trend is driven by the intensive development of cutting-edge gene correction methods for heart pathologies. However, military conflicts are hindering the execution of global trials for new treatments, while global supply chain disruptions are impeding the procurement of rare chemical components essential for the company's high-tech developments.

Tenaya Therapeutics Inc (TNYA) - Amount of Current Liabilities from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for Tenaya (TNYA)

- current quotes and average value forecast:
Price Chart Tenaya Therapeutics Inc|TNYA - Fair Value Consensus
- market capitalization information:
Market Valuation Tenaya Therapeutics, Inc.|TNYA - Aggregate Business Value
- balance sheet net asset value indicators:
Accounting Value per Share Tenaya Therapeutics|TNYA - Total Net Assets|Market Capitalization to Book Value Ratio tenayatherapeutics.com|TNYA - Company Assets
- business debt structure and liquidity details:
Debt to Equity Tenaya Therapeutics|TNYA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Tenaya Therapeutics Inc|TNYA - Company Aggregate Debts|Debt to Book Value Tenaya Therapeutics, Inc.|TNYA - Long-Term Debt|Company Short-Term Debts Tenaya Therapeutics|Quick Liquidity Indicator tenayatherapeutics.com
- earnings and valuation multiples indicators:
TNYA - Final Profit
Analysis of all company metrics:tenayatherapeutics.com - TNYA
Mass-produced product of Tenaya

Liquidity analysis is critical for identifying fundamental leaders in biopharmaceuticals. This metric aggregates all obligations maturing within one year, allowing for the rapid diagnosis of cash gap risks. For Tenaya Therapeutics (TNYA), with its research-intensive developments in gene therapy, such payments reflect the cost of maintaining patent protection. By analyzing the level of short-term liabilities, an investor assesses the balance between financial stability and resources for expansion.

Main competitors

REGN - Company Short-Term Debt|Company Short-Term Loans and Borrowings IRTC (iRhythm Technologies, Inc.)|LNTH (Lantheus Medical Imaging) - Company Current Liabilities|MLYS: Amount of Current Liabilities|Company Current Liabilities HTFL|KMTS (kestramedical.com) - Amount of Current Liabilities|Company Short-Term Debts ESPR|AMRN - Short-Term Debt|Company Short-Term Debt Anteris Technologies AVR|CVRX: Company Short-Term Indebtedness|Milestone Pharmaceuticals - Company Short-Term Debts|CRDL - Company Short-Term Debts|BEAT (HeartBeam) - Company Current Liabilities|Short-Term Debt Tenax Therapeutics Inc. (TENX)|ADGM (Adagio Medical Holdings Inc.) - Company Short-Term Debts|Company Short-Term Debts BioCardia Inc|Company Current Liabilities VTAK (Catheter Precision)|ABIO (arcabio.com) - Company Short-Term Loans and Borrowings|Acasti Pharma Inc. - Company Current Liabilities|Amount of Current Liabilities AVTE (Aerovate Therapeutics Inc.)|Verve - Company Short-Term Debts|Company Short-Term Loans and Borrowings WINT (Windtree Therapeutics)